Portfolio Lab

Regeneron Pharmaceuticals, Inc.

  • Stock
  • Ticker REGN
  • ISIN US75886F1075
  • Nasdaq

Health care · Pharmaceuticals · USA

$920.69 −0.29%
Close of 20 Nov 2026
Open in backtest

Performance, volatility and drawdowns of Regeneron Pharmaceuticals, Inc. since 11/2016, with distributions reinvested and calculated in US dollars. As of 20 Nov 2026.

Performance

REGNGlobal equities (VT)

$10,000 grew to $22,940. Global equities (VT): $29,042.

Distributions reinvested, before taxes and brokerage costs. Dashed: Global equities (VT) for comparison.

Declines from the peak

Lowest point −59.7% in 06/2025, measured from the peak in 08/2024. The old peak has not been reached again yet.

1-year return
+25.5%
5-year return p.a.
+7.3%
10-year return p.a.
+8.7%
Volatility p.a.
32.0%
Largest decline
−59.7%

Financial statements

Amounts in $ millions from filings with the SEC, earnings per share in $; fourth quarter and quarterly cash flow derived from year-to-date figures

Quarter end12/202403/202506/202509/202512/202503/202606/202609/2026
Income statement
Revenue3,7893,0293,6763,7543,8843,6054,2915,116
Operating income9905921,0801,0278806431,2942,048
EBITDA1,1177191,2151,1641,0257661,4172,169
Net income9188091,3921,4608457271,2971,949
Earnings per share8.117.2712.8113.627.876.7512.2318.45
Balance sheet
Total assets37,75937,54538,21940,16940,55940,86941,73144,405
Liabilities8,4068,1588,2809,2129,3029,44510,01910,907
Equity29,35429,38829,93930,95831,25731,42431,71133,499
Cash2,4883,0901,9962,5063,1182,9632,4563,659
Long-term debt1,9841,9851,9851,9861,9861,9861,9871,987
Cash flow
Operating cash flow1,2631,0451,1441,6191,1711,0798131,783
Capital expenditure-200-229-219-201-249-231-240-300
Free cash flow1,0638169251,4179228485731,483

Value it:DCF calculatorMultiples calculator

Annual returns

Best year 2021 at +30.7%, weakest 2024 at −18.9%. 7 of 9 full years were positive. * partial year.

Quarterly reports

Filing date with the SEC and earnings per share of the quarter

DayEarnings per share
30 Oct 2026$18.45
30 Jul 2026$12.23
29 Apr 2026$6.75
4 Feb 2026$7.87
28 Oct 2025$13.62
1 Aug 2025$12.81
29 Apr 2025$7.27
5 Feb 2025$8.11
31 Oct 2024$11.54
1 Aug 2024$12.41
2 May 2024$6.27
5 Feb 2024$10.20

Key metrics

Metrics of 15 Nov 2026; P/E, P/B, P/S, market cap and dividend yield at the last close.

Valuation

Market cap
€88bn
Market cap in trading currency
$97.2bn
Enterprise value
$89.9bn
P/E
20.3
P/S
5.75
P/B
2.90
EV/Sales
5.32
EV/EBITDA
16.7
Earnings yield
4.9%
FCF yield
3.9%

Results (last four quarters)

Revenue
$16.9bn
Gross profit
–
EBITDA
$5.38bn
Net income
$4.82bn
Earnings per share
$45.30
Revenue per share
$160.00
Revenue growth
+36.3%
Earnings growth
+33.5%

Profitability

Gross margin
–
Operating margin
28.8%
Net margin
28.5%
Return on equity
14.9%
Return on assets
10.8%

Balance sheet and cash flow

Cash
$9.30bn
Cash per share
$88.08
Financial debt
$1.99bn
Debt/equity %
6
Current ratio
3.35
Book value per share
$317.22
Operating cash flow
$4.85bn
Free cash flow
$3.83bn

Dividend

Dividend yield
0.40%
Dividend (12 months)
$3.70
Yield (12 months)
0.40%
Payout ratio
8%
Ex-dividend date
18 Aug 2026

Shares and trading

Shares outstanding
106m
Volume
855,281
Avg. volume 3 months
802,129
Relative volume
1.1

Price and technicals

Price
$920.69
1 day
−0.3%
52-week high
$973.36
52-week low
$600.66
Distance to 52-week high
−5.4%
Distance to 52-week low
+53.3%
Distance to 50-day line
+11.0%
Distance to 200-day line
+22.5%
RSI (14)
57
Volatility 1M
54.0%

Performance

1 week
−3.6%
1 month
+12.4%
3 months
+11.1%
6 months
+44.1%
YTD
+19.3%
1 year
+31.0%

Dates

Fiscal year end
31 Dec 2025
Most recent quarter
30 Sep 2026

Frequently asked questions

How has REGN performed since 11/2016?

$10,000 grew to $22,940 by 20 Nov 2026, which is +8.7% per year. Distributions are reinvested; taxes and brokerage costs are not deducted.

How volatile is REGN?

Volatility was 32.0% per year, measured on monthly returns. The largest decline from a peak was −59.7%, with the low in 06/2025.

How does REGN compare with a broad equity ETF?

Over the same period Global equities (VT) returned +11.3% per year at 15.1% volatility, REGN returned +8.7% at 32.0%. The correlation of monthly returns was 0.06; 1 would mean they moved in lockstep.

Which currency are the figures in?

In US dollars, the currency of the US listing.

Not investment advice. Metrics and financial statements calculated from the company's mandatory filings with the SEC, without guarantee; amounts in US dollars.

Reference data of securities: source ESMA (FIRDS reference data) and SEC (EDGAR).

Not investment advice: results in Portfolio Lab are model calculations based on historical data and your inputs. Past performance is not a reliable indicator of future results.

Regeneron Pharmaceuticals, Inc. (REGN): Return and risk